SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer Journal Article

   

Authors:	Ichihara, E.; Westover, D.; Meador, C. B.; Yan, Y.; Bauer, J. A.; Lu, P.; Ye, F.; Kulick, A.; de Stanchina, E.; McEwen, R.; Ladanyi, M.; Cross, D.; Pao, W.; Lovly, C. M.
Article Title:	SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer
Abstract:	Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of EGFR-mutant lung cancer. Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with EGFR-mutant lung cancer. Despite promising results, therapeutic efficacy is limited by the development of acquired resistance. Here we report that Src family kinases (SFK) and focal adhesion kinase (FAK) sustain AKT and MAPK pathway signaling under continuous EGFR inhibition in osimertinib-sensitive cells. Inhibiting either the MAPK pathway or the AKT pathway enhanced the effects of osimertinib. Combined SFK/FAK inhibition exhibited the most potent effects on growth inhibition, induction of apoptosis, and delay of acquired resistance. SFK family member YES1 was amplified in osimertinib-resistant EGFR-mutant tumor cells, the effects of which were overcome by combined treatment with osimertinib and SFK inhibitors. In conclusion, our data suggest that the concomitant inhibition of both SFK/FAK and EGFR may be a promising therapeutic strategy for EGFR-mutant lung cancer. ©2017 AACR.
Journal Title:	Cancer Research
Volume:	77
Issue:	11
ISSN:	0008-5472
Publisher:	American Association for Cancer Research
Date Published:	2017-06-01
Start Page:	2990
End Page:	3000
Language:	English
DOI:	10.1158/0008-5472.can-16-2300
PROVIDER:	scopus
PMCID:	PMC5467531
PUBMED:	28416483
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020760401&doi=10.1158%2f0008-5472.CAN-16-2300&partnerID=40&md5=998fa045d2d7f2d02caa03d992e995c6
Notes:	Article -- Export Date: 3 July 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/112441